Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering

Bibliography

• Data for 2003. Available from: http://www.cdc.gov/nccdphp/overview_text.htm
   Google Scholar
• Bjorkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 2006;260(6):493-508
   PubMed Web of Science ®Google Scholar
• Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med 2007;7(2):199-218
   PubMed Web of Science ®Google Scholar
• Pikuleva IA. Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos 2006;34(4):513-20
   PubMed Web of Science ®Google Scholar
• Pikuleva IA. Cytochrome P450s and cholesterol homeostasis. Pharmacol Ther 2006;112:761-73
   PubMed Web of Science ®Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Ann Rev Biochem 2003;72:137-74
   PubMed Web of Science ®Google Scholar
• Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 2004;40(3):539-51
   PubMed Web of Science ®Google Scholar
• Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Ann Rev Cell Dev Biol 2000;16:459-81
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39
   PubMed Web of Science ®Google Scholar
• Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86(12A):19L-22L
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62(5):707-14
   PubMed Web of Science ®Google Scholar
• Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26(5):1513-7
   PubMed Web of Science ®Google Scholar
• Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 2006;98(11):1542-9
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3(2):213-9
   PubMedGoogle Scholar
• Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80(13):4124-8
   PubMed Web of Science ®Google Scholar
• Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004;47(2):73-104
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005;45:89-118
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-90
   PubMed Web of Science ®Google Scholar
• Shepherd J, Packard CJ, Bicker S, et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302(22):1219-22
   PubMed Web of Science ®Google Scholar
• Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm 2002;59(10):932-9
   PubMed Web of Science ®Google Scholar
• Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341(7):498-511
   PubMed Web of Science ®Google Scholar
• Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008;6(4):447-70
   PubMedGoogle Scholar
• Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106(15):1943-8
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008;62(1):88-96
   PubMed Web of Science ®Google Scholar
• Malik S, Kashyap ML. Niacin, lipids, and heart disease. Curr Cardiol Rep 2003;5(6):470-6
   PubMedGoogle Scholar
• Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Ann Rev Pharmacol Toxicol 2008;48:79-106
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345(22):1583-92
   PubMed Web of Science ®Google Scholar
• Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008;101(8A):3B-8B
   Web of Science ®Google Scholar
• Venkatesh PK, Caskey D, Reddy PC. Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. Am J Med Sci 2008;336(1):64-8
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag 2008;4(1):131-41
   PubMedGoogle Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-93
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171(1):1-13
   PubMed Web of Science ®Google Scholar
• Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005;1(4):317-31
   PubMedGoogle Scholar
• Meuwese MC, Franssen R, Stroes ES, Kastelein JJ. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors. Curr Opin Lipidol 2006;17(4):426-30
   PubMed Web of Science ®Google Scholar
• Van Leuven SI, Stroes ES, Kastelein JJ. High-density lipoprotein: a fall from grace? Ann Med 2008;1-10 [Epub ahead of print]
   Google Scholar
• Elsayed RK, Evans JD. Emerging lipid-lowering drugs: squalene synthase inhibitors. Expert Opin Emerging Drugs 2008;13(2):309-22
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov
   Google Scholar
• Myant NB, Mitropoulos KA. Cholesterol 7a-hydroxylase. J Lipid Res 1977;18:135-53
   PubMed Web of Science ®Google Scholar
• Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002;110(1):109-17
   PubMed Web of Science ®Google Scholar
• The American Heart Association. Available from: http://www.americanheart.org/presenter.jhtml?identifier183
   Google Scholar
• Bjorkhem I, Reihner E, Angelin B, et al. On the possible use of the serum level of 7 alpha-hydroxycholesterol as a marker for increased activity of the cholesterol 7 alpha-hydroxylase in humans. J Lipid Res 1987;28(8):889-94
   PubMed Web of Science ®Google Scholar
• Nicolau VA, Shefer S, Salen G, Mosbach EH. Determination of hepatic cholesterol 7a-hydroxylase activity in man. J Lipid Res 1974;15:146-51
   PubMed Web of Science ®Google Scholar
• Reihner E, Angelin B, Rudling M, et al. Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. J Lipid Res 1990;31(12):2219-26
   PubMed Web of Science ®Google Scholar
• Oda H, Yamashita H, Kosahara K, et al. Esterified and total 7 alpha-hydroxycholesterol in human serum as an indicator for hepatic bile acid synthesis. J Lipid Res 1990;31(12):2209-18
   PubMed Web of Science ®Google Scholar
• Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther 2006;10(2):93-100
   PubMed Web of Science ®Google Scholar
• Bertolotti M, Abate N, Bertolotti S, et al. Effect of aging on cholesterol 7 alpha-hydroxylation in humans. J Lipid Res 1993;34(6):1001-7
   PubMed Web of Science ®Google Scholar
• Cheema SK, Cikaluk D, Agellon LB. Dietary fats modulate the regulatory potential of dietary cholesterol on cholesterol 7 alpha-hydroxylase gene expression. J Lipid Res 1997;38(2):315-23
   PubMed Web of Science ®Google Scholar
• Kurushima H, Hayashi K, Shingu T, et al. Opposite effects on cholesterol metabolism and their mechanisms induced by dietary oleic acid and palmitic acid in hamsters. Biochim Biophys Acta 1995;1258(3):251-6
   PubMed Web of Science ®Google Scholar
• Bravo E, Flora L, Cantafora A, et al. The influence of dietary saturated and unsaturated fat on hepatic cholesterol metabolism and the biliary excretion of chylomicron cholesterol in the rat. Biochim Biophys Acta 1998;1390(2):134-48
   PubMed Web of Science ®Google Scholar
• Lakshmanan MR, Veech RL. Short- and long-term effects of ethanol administration in vivo on rat liver HMG-CoA reductase and cholesterol 7alpha-hydroxylase activities. J Lipid Res 1977;18(3):325-30
   PubMed Web of Science ®Google Scholar
• Stahlberg D, Rudling M, Angelin B, et al. Hepatic cholesterol metabolism in human obesity. Hepatology 1997;25(6):1447-50
   PubMed Web of Science ®Google Scholar
• Wang J, Freeman DJ, Grundy SM, et al. Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest 1998;101(6):1283-91
   PubMed Web of Science ®Google Scholar
• Couture P, Otvos JD, Cupples LA, et al. Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res 1999;40(10):1883-9
   PubMed Web of Science ®Google Scholar
• Hofman MK, Groenendijk M, Verkuijlen PJJH, et al. Modulating effect of the A-278 promoter polymorphism in the cholesterol 7alpha-hydroxylase gene on serum lipid levels in normolipidaemic and hypertriglyceridaemic individuals. Eur J Hum Genet 2004;12:935-41
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Krapivner S, Gustafsson U, et al. Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. Atherosclerosis 2005;182:37-45
   PubMed Web of Science ®Google Scholar
• Hegele RA, Wang J, Harris SB, et al. Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis 2001;154(3):579-87
   PubMed Web of Science ®Google Scholar
• Hofman MK, Weggemans RM, Zock PL, et al. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J Nutr Biochem 2004;134:2200-4
   Google Scholar
• Kovar J, Suchanek P, Hubacek JA, Poledne R. The A-204C polymorphism in the cholesterol 7alpha-hydroxylase (CYP7A1) gene determines the cholesterolemia responsiveness to a high-fat diet. Physiol Res 2004;53(5):565-8
   PubMed Web of Science ®Google Scholar
• Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2004;175(2):287-93
   PubMed Web of Science ®Google Scholar
• Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 2005;180(2):407-15
   PubMed Web of Science ®Google Scholar
• Einarsson K, Angelin B, Ewerth S, et al. Bile acid synthesis in man: assay of hepatic microsomal cholesterol 7 alpha-hydroxylase activity by isotope dilution-mass spectrometry. J Lipid Res 1986;27(1):82-8
   PubMed Web of Science ®Google Scholar
• Axelson M, Bjorkhem I, Reihner E, Einarsson K. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 1991;284(2):216-8
   PubMed Web of Science ®Google Scholar
• Eusufzai S, Axelson M, Angelin B, Einarsson K. Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 1993;34(5):698-701
   PubMed Web of Science ®Google Scholar
• Sauter GH, Munzing W, Von Ritter C, Paumgartner G. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci 1999;44(1):14-9
   PubMed Web of Science ®Google Scholar
• Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003;44(4):859-66
   PubMed Web of Science ®Google Scholar
• Lovgren-Sandblom A, Heverin M, Larsson H, et al. Novel LC-MS/MS method for assay of 7alpha-hydroxy-4-cholesten-3-one in human plasma. Evidence for a significant extrahepatic metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856(1-2):15-9
   PubMed Web of Science ®Google Scholar
• Duane WC, Javitt NB. 27-hydroxycholesterol: production rates in normal human subjects. J Lipid Res 1999;40(7):1194-9
   PubMed Web of Science ®Google Scholar
• Lund E, Andersson O, Zhang J, et al. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 1996;16(2):208-12
   PubMed Web of Science ®Google Scholar
• Babiker A, Andersson O, Lund E, et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem 1997;272(42):26253-61
   PubMed Web of Science ®Google Scholar
• Song C, Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 2000;141(11):4180-4
   PubMed Web of Science ®Google Scholar
• Fu X, Menke JG, Chen Y, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001;276(42):38378-87
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Diczfalusy U. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 2002;22(5):734-42
   PubMed Web of Science ®Google Scholar
• Javitt NB. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J Lipid Res 2002;43(5):665-70
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Boberg KM, Leitersdorf E. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. In: Scriver AL, Beaudet al, Sly WS, editors, The metabolic and molecular bases of inherited disease. 7th edition. New York: McGraw-Hill; 1995. p. 2073-99
   Google Scholar
• Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol 2005;62(9):1459-63
   PubMed Web of Science ®Google Scholar
• Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19(4):792-802
   PubMed Web of Science ®Google Scholar
• Shukla A, Sharma MK, Jain A, Goel PK. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients a controlled randomized trial. Indian Heart J 2005;57(6):675-80
   PubMedGoogle Scholar
• Chen W, Chiang JY. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 2003;313:71-82
   PubMed Web of Science ®Google Scholar
• Ellis E, Axelson M, Abrahamsson A, et al. Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 2003;38(4):930-8
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001;12(2):105-12
   PubMed Web of Science ®Google Scholar
• Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 2003;25(1):72-8
   PubMed Web of Science ®Google Scholar
• Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 2005;16(2):193-212
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Lutjohann D, Diczfalusy U, et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 1998;39(8):1594-600
   PubMed Web of Science ®Google Scholar
• Lutjohann D, Breuer O, Ahlborg G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 1996;93(18):9799-804
   PubMed Web of Science ®Google Scholar
• Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 1999;96(13):7238-43
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Andersson U, Ellis E, et al. From brain to bile. Evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) in humans. J Biol Chem 2001;276(40):37004-10
   PubMed Web of Science ®Google Scholar
• Heverin M, Bogdanovic N, Lutjohann D, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 2004;45(1):186-93
   PubMed Web of Science ®Google Scholar
• Kotti TJ, Ramirez DM, Pfeiffer BE, et al. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 2006;103(10):3869-74
   PubMed Web of Science ®Google Scholar
• Available from: www.alzforum.org
   Google Scholar
• Chen W, Chen G, Head DL, et al. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab 2007;5(1):73-9
   PubMed Web of Science ®Google Scholar
• Cao G, Bales KR, Demattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res 2007;4(2):179-84
   PubMed Web of Science ®Google Scholar
• Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, et al. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 2006;281(18):12799-808
   PubMed Web of Science ®Google Scholar
• Brown J 3rd, Theisler C, Silberman S, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 2004;279(33):34674-81
   PubMed Web of Science ®Google Scholar
• Famer D, Meaney S, Mousavi M, et al. Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 2007;359(1):46-50
   PubMed Web of Science ®Google Scholar
• Ohyama Y, Meaney S, Heverin M, et al. Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem 2006;281(7):3810-20
   PubMed Web of Science ®Google Scholar
• Milagre I, Nunes MJ, Gama MJ, et al. Transcriptional regulation of the human CYP46A1 brain-specific expression by Sp transcription factors. J Neurochem 2008;106(2):835-49
   PubMed Web of Science ®Google Scholar
• Mast N, White MA, Bjorkhem I, et al. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci USA 2008;105(28):9546-51
   PubMed Web of Science ®Google Scholar
• Mast N, Norcross R, Andersson U, et al. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry 2003;42(48):14284-92
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 2001;29(7):1029-34
   PubMed Web of Science ®Google Scholar
• Wester MR, Yano JK, Schoch GA, et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 2004;279(34):35630-7
   PubMed Web of Science ®Google Scholar
• Locuson CW, Gannett PM, Ayscue R, Tracy TS. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem 2007;50(6):1158-65
   PubMed Web of Science ®Google Scholar
• Liu KH, Kim MJ, Jung WM, et al. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos 2005;33(2):209-13
   PubMed Web of Science ®Google Scholar
• Poulos TL, Johnson EF. Structures of cytochrome P450 enzymes. In: Montellano PROD, editor, Cytochrome P450: structure, mechanism, and biochemistry. 3rd edition. New York: Kluwer Academic/Plenum Publishers; 2005. p. 87-114
   Google Scholar
• Williams PA, Cosme J, Sridhar V, et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000;5(1):121-31
   PubMed Web of Science ®Google Scholar
• Mast N, Liao W-L, Pikuleva IA, Turko IV. Mass spectrometry identification of membrane-interacting peptides suggests membrane topology of cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase (submitted). Arch Biochem Biophys 2008 [review]
   Google Scholar
• Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24(5):806-15
   PubMed Web of Science ®Google Scholar
• Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004;41(1):7-10
   PubMed Web of Science ®Google Scholar
• Reiss AB. Cholesterol and apolipoprotein E in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2005;20(2):91-6
   PubMedGoogle Scholar
• Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int 2007;50(1):12-38
   PubMed Web of Science ®Google Scholar
• Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25(2):178-202
   PubMedGoogle Scholar
• Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor, Cytochrome P450. 3rd edition. New York, Boston, Dordrecht, London, Moscow: Kluwer Academic/Plenum Publishers; 2005. p. 377-530
   Google Scholar
• Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 2005;97(2):177-83
   PubMed Web of Science ®Google Scholar
• Michael LF, Schkeryantz JM, Burris TP. The pharmacology of LXR. Mini Rev Med Chem 2005;5(8):729-40
   PubMed Web of Science ®Google Scholar
• Available from: http://xray.bmc.uu.se/usf/voidoo.html
   Google Scholar
• Available from: http://loschmidt.chemi.muni.cz/caver/online.php
   Google Scholar